E3

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Cardiometabolic care tracks glucose and blood pressure

HRR Testing Moves Upfront in Prostate Cancer

ALS Immune Signals Depend on Where You Look

A Self-Guided Pathway for Functional Seizures

Cardiac amyloidosis is no longer the whole story of protein misfolding

Brown fat is looking less like a metabolic curiosity and more like a drug target

A Second Step for Alzheimer’s Blood Tests

Enhertu Stumbles in Early Breast Cancer

A Genetic Clue to Spinal Leukodystrophy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
